The Food and Drug Administration on Thursday gave its approval to Leqembi, a drug designed to slow the progression of Alzheimer’s disease. Leqembi is not considered a cure for Alzheimer’s, but will be covered by Medicare. Dr. Jon LaPook has more.
Be the first to know
Get browser notifications for breaking news, live events, and exclusive reporting.